BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic collaboration with Inland Psychiatric Medical Group ("IPMG"), an established provider of comprehensive behavioral health services across Southern California.

IPMG operates a multidisciplinary behavioral health practice serving patients throughout Southern California, including in Riverside, San Bernardino, Los Angeles, and Orange Counties. Its comprehensive clinical services include psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment, and clinical research.

The collaboration with BrainsWay includes a multisystem order of BrainsWay Deep TMS systems planned for installation at IPMG clinics, and the exploration of a range of scientific, clinical and research projects designed to expand the possibilities of interventional psychiatry and mental health care for the benefit of patients and providers.

BrainsWay Deep TMS is an innovative therapy delivered through a patented and unique coil design which is housed within a cushioned, patient and provider-friendly helmet. By pulsing a magnetic field that targets affected structures of the brain, the Deep TMS system is capable of stimulating underactive neural networks. The system is currently FDA-cleared to treat major depressive disorder both with and without anxiety symptoms, obsessive-compulsive disorder (OCD), and smoking addiction.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.